Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5-31040 | Other Grant/Funding Number | Emory U19 grant Award account number 5-31040 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Biomedical Lay Summary Title: Characterization of immune response to vaccination in patients receiving single-drug immunosuppressive therapy Principal Investigator: Robert Swerlick, MD Other Investigators: Rafi Ahmed, PhD Suephy Chen, MD Jens Wrammert, PhD Adam Sperduto
We plan to give three different groups of participants influenza vaccinations and measure each participant's immune system response through blood tests. The three groups will be:
All participants will be between 18 - 89 years old and will not have had influenza vaccination within the previous six months. We will administer the vaccination on day 0. We will take blood samples on days 0, 7, and 28 following vaccination. We will use these blood samples to measure the amount of antibodies produced to the vaccine and the response of specific immune system cells known as B-lymphocytes. Using statistical methods, we will compare these findings between the three groups of participants to determine if differences in response to the vaccination exist.
3. How the research will advance scientific knowledge and/or human health To our knowledge there is no scientific data available regarding the effectiveness of vaccinations in patients receiving only one specific immunosuppressive medication. We will also be using new techniques developed at Emory to measure the B-lymphocyte response to the vaccine. This research could potentially help guide vaccination strategies for people requiring immunosuppressive medications and prevent infectious disease in these populations as well as the general population.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy Volunteer | Placebo Comparator | Healthy volunteers without skin disease that received administration of Fluzone |
|
| Azathioprine | Experimental | Patients with skin diseases taking azathioprine that received administration of Fluzone |
|
| TNF alpha blocker | Experimental | Patients with skin diseases taking azathioprine that received administration of Fluzone |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flu Vaccine | Biological | Administration of Fluzone (Influenza Vaccine) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination | Influenza hemagluttination inhibition titers were measured against H3N2 Perth before and after influenza vaccination. Titers greater than or equal to 1:40 constitute a protective response to influenza strains. | 28 days |
| Influenza Hemagluttination Inhibition Titers Measured Against Pandemic H1N1 Strains Before and After Influenza Vaccination | Influenza hemagluttination inhibition titers were measured against pandemic H1N1 strains before and after influenza vaccination. Titers greater than or equal to 1:40 constitute a protective response to influenza strains. | 28 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Robert Swerlick, MD | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emory University, Department of Dermatology | Atlanta | Georgia | 30322 | United States | ||
| Emory University |
Not provided
43 subjects enrolled from Dept of dermatology, including 21 normal controls, 12 patients on TNF blockers for the treatment of skin diseases, and 10 patients treated with azathioprine for the treatment of skin diseases. Both serologic and cell based assays were completed before and after vaccination on all subjects.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Healthy Volunteer | |
| FG001 | Azathioprine | |
| FG002 | TNF Alpha Blockers |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Healthy Volunteer | Healthy volunteers without skin disease prior to influenza vaccination |
| BG001 | Azathioprine | Patients with skin diseases taking azathioprine |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Influenza Hemagluttination Inhibition Titers Measured Against H3N2 Perth Before and After Influenza Vaccination | Influenza hemagluttination inhibition titers were measured against H3N2 Perth before and after influenza vaccination. Titers greater than or equal to 1:40 constitute a protective response to influenza strains. | Posted | Number | participants | 28 days |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Healthy Volunteer Pre-vaccination | Healthy volunteers who had blood drawn prior to vaccination with influenza vaccine |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Robert Swerlick | Emory University | 404-727-3669 | rswerli@emory.edu |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D007252 | Influenza Vaccines |
| ID | Term |
|---|---|
| D014765 | Viral Vaccines |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Atlanta |
| Georgia |
| 30322 |
| United States |
| BG002 | TNF Alpha Blocker | Patients with skin diseases taking TNF alpha blockers |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| TNF Alpha Blockers |
Patients with skin diseases taking TNF alpha blockers |
|
|
| Primary | Influenza Hemagluttination Inhibition Titers Measured Against Pandemic H1N1 Strains Before and After Influenza Vaccination | Influenza hemagluttination inhibition titers were measured against pandemic H1N1 strains before and after influenza vaccination. Titers greater than or equal to 1:40 constitute a protective response to influenza strains. | Posted | Number | participants | 28 days |
|
|
|
| 0 |
| 21 |
| 0 |
| 21 |
| EG001 | Healthy Volunteer Post-vaccination | Healthy volunteers who had blood drawn after vaccination with influenza vaccine | 0 | 21 | 0 | 21 |
| EG002 | Azathioprine Pre-vaccination | Patients with skin disease treated with azathioprine who had blood drawn prior to vaccination with influenza vaccine | 0 | 10 | 0 | 10 |
| EG003 | Azathioprine Post-vaccination | Patients with skin disease treated with azathioprine who had blood drawn after vaccination with influenza vaccine | 0 | 10 | 0 | 10 |
| EG004 | TNF Alpha Blocker Pre-vaccination | Patients with skin disease treated with TNF blockers who had blood drawn prior to vaccination with influenza vaccine | 0 | 12 | 0 | 12 |
| EG005 | TNF Alpha Blocker Post-vaccination | Patients with skin disease treated with TNF blockers who had blood drawn after vaccination with influenza vaccine | 0 | 12 | 0 | 12 |
Not provided
Not provided
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |